Oncology Corporate Profile
Arrowhead Research Corporation is a clinical stage nanomedicine company developing innovative therapies at the interface of biology and nanoengineering. The Company has clinical programs in small RNA therapeutics and obesity. Arrowhead's programs are based on its proprietary drug development and delivery platforms, each capable of creating multiple therapeutic products. This strategy seeks to enhance the return potential for investors and reduce risk compared to traditional biotech companies. Arrowhead's world-class capabilities and intellectual property covering nucleic acid delivery, siRNA chemistry, and tissue targeting allow it to optimize therapeutic agents for a wide range of diseases.
|Brand / Product||Class||Area of Study||Phase||Partnership|
|cyclosert / CRLX-101||topoisomerase I inhibitor||Non Small Cell Lung Cancer (NSCLC)||II||Cerulean Pharma, Inc.|
|CALAA-01||RNAi therapeutic||Various cancer types||I||Calando Pharmaceuticals|
|cyclosert / CRLX-101||topoisomerase I inhibitor||Various cancer types||Preclinical||Tube Pharma|
|Unnamed||RNA antagonist (HIF-1 alpha antagonist)||Various cancer types||Research|
View additional information on product candidates here »
3/27/2017 07:04 pm
3/23/2017 11:03 am
[Business Wire] - Arrowhead Pharmaceuticals Inc. today announced that on March 21, 2017 it entered into a stockholder rights agreement in accordance with an authorization and declaration from its board of directors of a dividend distribution of one preferred share purchase right on each outstanding share of the company’s common stock.